Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb;34(3):366-372.
doi: 10.1080/14767058.2019.1608177. Epub 2019 Apr 24.

Prostaglandins and cesarean delivery for nonreassuring fetal status in patients delivering small-for-gestational age neonates at term

Joshua I Rosenbloom  1 , Janine S Rhoades  1 , Candice L Woolfolk  1 , Molly J Stout  1 , Methodius G Tuuli  1 , George A Macones  1 , Alison G Cahill  1
Affiliations

Prostaglandins and cesarean delivery for nonreassuring fetal status in patients delivering small-for-gestational age neonates at term

Joshua I Rosenbloom et al. J Matern Fetal Neonatal Med. 2021 Feb.

Abstract

Objective: Growth-restricted fetuses have been excluded from many randomized trials of prostaglandins for labor induction. As prostaglandins, particularly misoprostol, are associated with increased rates of cesarean delivery for nonreassuring fetal heart tracing, it is important to assess their safety in pregnancies at higher risk of this complication. The objective of this study was to estimate the association between use of prostaglandins for labor induction in term singleton pregnancies complicated by delivery of small-for-gestational age (SGA) neonates and the risk of cesarean delivery for nonreassuring fetal status (NRFS).Materials and methods: Retrospective cohort study of singleton deliveries ≥37 weeks following induction of labor in patients with SGA (birthweight <10% percentile for gestational age). Patients with prior cesarean delivery or neonates with major congenital anomalies were excluded. Patients were categorized by exposure to prostaglandins. The primary outcome was cesarean delivery for NRFS. Secondary outcomes were any cesarean delivery, a composite of a 5-min Apgar score <7, admission to the neonatal intensive care unit, or neonatal death, and a composite of maternal morbidity (transfusion, postpartum hemorrhage, wound infection, endometritis, fever). Propensity scores for exposure were estimated using a logistic regression model, including parity, comorbidities, and Bishop score. Stabilized weights from inverse probability of treatment weighting were used. Outcomes were compared with relative risks (RRs) and 95% confidence intervals (CIs).Results: There were 1097 patients: 587 (53.5%) exposed to prostaglandins and 510 (46.5%) unexposed. Covariates were balanced in the stabilized sample. Overall, 166 (15.1%) patients had cesarean deliveries for NRFS. In unadjusted analysis, prostaglandin use was associated with an increased RR of cesarean for NRFS (18.3 versus 11.0%, RR: 1.71, 95% CI: 1.27-2.30). In propensity-score-weighted analysis, the RR for cesarean for NRFS was 1.22 (95% CI: 0.93-1.59). There was no significant association between prostaglandin exposure and all-cause cesarean delivery, maternal morbidity, or neonatal morbidity.Conclusion: In propensity score analysis, there was no association between the use of prostaglandins for labor induction at term and cesarean for NRFS in pregnancies complicated by SGA. However, given the retrospective nature of the study, these results should be interpreted with caution.

Keywords: Cesarean delivery; induction of labor; nonreassuring fetal heart tracing; prostaglandins; small-for-gestational age.

PubMed Disclaimer

Conflict of interest statement

Disclosure Statement: The authors report no conflicts of interest.

Figures

Figure 1:
Figure 1:
Study flow diagram for enrollment and inclusion in analysis.
See this image and copyright information in PMC

References

    1. Martin JA, Hamilton BE, Osterman MJ, Driscoll AK, Mathews TJ. Births: Final Data for 2015. Natl Vital Stat Rep. 2017;66(1):1. - PubMed
    1. Carbone JF, Tuuli MG, Fogertey PJ, Roehl KA, Macones GA. Combination of Foley bulb and vaginal misoprostol compared with vaginal misoprostol alone for cervical ripening and labor induction: a randomized controlled trial. Obstet Gynecol. 2013;121(2 Pt 1):247–52. - PubMed
    1. Levine LD, Downes KL, Elovitz MA, Parry S, Sammel MD, Srinivas SK. Mechanical and Pharmacologic Methods of Labor Induction: A Randomized Controlled Trial. Obstet Gynecol. 2016;128(6):1357–64. - PMC - PubMed
    1. Ten Eikelder ML, Oude Rengerink K, Jozwiak M, de Leeuw JW, de Graaf IM, van Pampus MG, Holswilder M, Oudijk MA, van Baaren GJ, Pernet PJ, Bax C, van Unnik GA, Martens G, Porath M, van Vliet H, Rijnders RJ, Feitsma AH, Roumen FJ, van Loon AJ, Versendaal H, Weinans MJ, Woiski M, van Beek E, Hermsen B, Mol BW, Bloemenkamp KW. Induction of labour at term with oral misoprostol versus a Foley catheter (PROBAAT-II): a multicentre randomised controlled non-inferiority trial. Lancet. 2016;387(10028):1619–28. - PubMed
    1. Kalafat E, Morales-Rosello J, Thilaganathan B, Tahera F, Khalil A. Risk of operative delivery for intrapartum fetal compromise in small-for-gestational-age fetuses at term: an internally validated prediction model. Am J Obstet Gynecol. 2018;218(1):134 e1–e8. - PubMed